Uso clínico de Psilocibina en trastornos mentales: un análisis bibliométrico en Scopus y Web of Science
DOI:
https://doi.org/10.18041/2619-4465/interfaces.2.13409Palabras clave:
Terapia asistida por psicodélicos, Depresión resistente al tratamiento, Neurofarmacología de los psicodélicos, Potencial terapéutico, PsilocibinaResumen
Este estudio presenta un análisis cienciométrico de la literatura científica sobre el uso clínico de la psilocibina en trastornos mentales, abarcando publicaciones entre 2023 y 2025. El objetivo es identificar las tendencias de investigación, las redes de colaboración y el impacto científico de este campo en rápida evolución. Se recuperaron un total de 359 registros únicos de Scopus y Web of Science, los cuales fueron analizados mediante Gephi y Google Colab para el modelado de redes. Los resultados revelan un crecimiento exponencial en la producción, con un aumento del 1375% en las publicaciones entre 2023 y 2024. Estados Unidos lideró la producción, aportando el 44,4% del total de artículos y el 41,1% de las citas, seguido por Canadá y Suiza. El análisis identificó tres áreas de investigación predominantes: los mecanismos neurofarmacológicos, el tratamiento de la depresión resistente y la integración de componentes espirituales y existenciales en las terapias asistidas por psicodélicos. Este estudio ofrece una visión integral del panorama actual, destacando la transición de la psilocibina de una sustancia proscrita a una herramienta terapéutica legítima y prometedora para la salud mental contemporánea.
Descargas
Referencias
[1]D. Telles-Correia, S. Saraiva, and J. Gonçalves, “Mental Disorder-The Need for an Accurate Definition,” Front Psychiatry, vol. 9, p. 64, Mar. 2018, doi: 10.3389/fpsyt.2018.00064. Available: http://dx.doi.org/10.3389/fpsyt.2018.00064
[2]J. C. Wakefield, “The concept of mental disorder. On the boundary between biological facts and social values,” Am Psychol, vol. 47, no. 3, pp. 373–388, Mar. 1992, doi: 10.1037//0003-066x.47.3.373. Available: http://dx.doi.org/10.1037//0003-066x.47.3.373
[3]R. L. Carhart-Harris et al., “Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin,” Proc Natl Acad Sci U S A, vol. 109, no. 6, pp. 2138–2143, Feb. 2012, doi: 10.1073/pnas.1119598109. Available: http://dx.doi.org/10.1073/pnas.1119598109
[4]D. J. Stein, A. C. Palk, and K. S. Kendler, “What is a mental disorder? An exemplar-focused approach,” Psychol Med, vol. 51, no. 6, pp. 894–901, Apr. 2021, doi: 10.1017/S0033291721001185. Available: http://dx.doi.org/10.1017/S0033291721001185
[5]N. H. Kalin, “The Critical Relationship Between Anxiety and Depression,” American Journal of Psychiatry, May 2020, doi: 10.1176/appi.ajp.2020.20030305. Available: https://psychiatryonline.org/doi/10.1176/appi.ajp.2020.20030305. [Accessed: Jul. 12, 2025]
[6]J. W. G. Tiller, “Depression and anxiety,” Medical Journal of Australia, vol. 199, pp. S28–S31, Oct. 2013, doi: 10.5694/mja12.10628. Available: https://onlinelibrary.wiley.com/doi/abs/10.5694/mja12.10628. [Accessed: Jul. 12, 2025]
[7]N. C. Jacobson and M. G. Newman, “Anxiety and depression as bidirectional risk factors for one another: A meta-analysis of longitudinal studies,” Psychol Bull, vol. 143, no. 11, pp. 1155–1200, Nov. 2017, doi: 10.1037/bul0000111. Available: http://dx.doi.org/10.1037/bul0000111
[8]C. M. Reiff et al., “Psychedelics and Psychedelic-Assisted Psychotherapy,” American Journal of Psychiatry, Feb. 2020, doi: 10.1176/appi.ajp.2019.19010035. Available: https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.19010035. [Accessed: Jul. 14, 2025]
[9]A. Garcia-Romeu and W. A. Richards, “Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions,” Int Rev Psychiatry, vol. 30, no. 4, pp. 291–316, Aug. 2018, doi: 10.1080/09540261.2018.1486289. Available: http://dx.doi.org/10.1080/09540261.2018.1486289
[10]J. J. H. Rucker, J. Iliff, and D. J. Nutt, “Psychiatry & the psychedelic drugs. Past, present & future,” Neuropharmacology, vol. 142, pp. 200–218, Nov. 2018, doi: 10.1016/j.neuropharm.2017.12.040. Available: http://dx.doi.org/10.1016/j.neuropharm.2017.12.040
[11]“Website.” Available: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.revistavertex.com.ar/ebooks/9Roemmers.pdf
[12]A. L. McGuire, H. F. Lynch, L. A. Grossman, and I. G. Cohen, “Pressing regulatory challenges for psychedelic medicine,” Science, vol. 380, no. 6643, pp. 347–350, Apr. 2023, doi: 10.1126/science.adg1324. Available: http://dx.doi.org/10.1126/science.adg1324
[13]D. E. Nichols, M. W. Johnson, and C. D. Nichols, “Psychedelics as Medicines: An Emerging New Paradigm,” Clin Pharmacol Ther, vol. 101, no. 2, pp. 209–219, Feb. 2017, doi: 10.1002/cpt.557. Available: http://dx.doi.org/10.1002/cpt.557
[14]D. B. Yaden, S. P. Goldy, B. Weiss, and R. R. Griffiths, “Clinically relevant acute subjective effects of psychedelics beyond mystical experience,” Nat. Rev. Psychol., vol. 3, no. 9, pp. 606–621, Sep. 2024, doi: 10.1038/s44159-024-00345-6. Available: https://www.nature.com/articles/s44159-024-00345-6
[15]M. Johnson, W. Richards, and R. Griffiths, “Human hallucinogen research: guidelines for safety,” J Psychopharmacol, vol. 22, no. 6, pp. 603–620, Aug. 2008, doi: 10.1177/0269881108093587. Available: http://dx.doi.org/10.1177/0269881108093587
[16]D. B. Yaden, D. Earp, M. Graziosi, D. Friedman-Wheeler, J. B. Luoma, and M. W. Johnson, “Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default,” Front Psychol, vol. 13, p. 873279, May 2022, doi: 10.3389/fpsyg.2022.873279. Available: http://dx.doi.org/10.3389/fpsyg.2022.873279
[17]S. Ross et al., “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial,” J Psychopharmacol, vol. 30, no. 12, pp. 1165–1180, Dec. 2016, doi: 10.1177/0269881116675512. Available: http://dx.doi.org/10.1177/0269881116675512
[18]A. K. Davis et al., “Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial,” JAMA Psychiatry, vol. 78, no. 5, pp. 481–489, May 2021, doi: 10.1001/jamapsychiatry.2020.3285. Available: http://dx.doi.org/10.1001/jamapsychiatry.2020.3285
[19]D. M. Horton, B. Morrison, and J. Schmidt, “Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy,” Am J Psychother, vol. 74, no. 4, pp. 140–149, Dec. 2021, doi: 10.1176/appi.psychotherapy.20200055. Available: http://dx.doi.org/10.1176/appi.psychotherapy.20200055
[20]G. M. Goodwin et al., “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression,” N Engl J Med, vol. 387, no. 18, pp. 1637–1648, Nov. 2022, doi: 10.1056/NEJMoa2206443. Available: http://dx.doi.org/10.1056/NEJMoa2206443
[21]R. E. Daws et al., “Increased global integration in the brain after psilocybin therapy for depression,” Nat Med, vol. 28, no. 4, pp. 844–851, Apr. 2022, doi: 10.1038/s41591-022-01744-z. Available: http://dx.doi.org/10.1038/s41591-022-01744-z
[22]S. T. Aaronson et al., “Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial,” JAMA Psychiatry, vol. 81, no. 6, pp. 555–562, Jun. 2024, doi: 10.1001/jamapsychiatry.2023.4685. Available: http://dx.doi.org/10.1001/jamapsychiatry.2023.4685
[23]G. Gründer et al., “Treatment with psychedelics is psychotherapy: beyond reductionism,” Lancet Psychiatry, vol. 11, no. 3, pp. 231–236, Mar. 2024, doi: 10.1016/S2215-0366(23)00363-2. Available: http://dx.doi.org/10.1016/S2215-0366(23)00363-2
[24]M. P. Bogenschutz et al., “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial,” JAMA Psychiatry, vol. 79, no. 10, pp. 953–962, Oct. 2022, doi: 10.1001/jamapsychiatry.2022.2096. Available: http://dx.doi.org/10.1001/jamapsychiatry.2022.2096
[25]S. Ross, “Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress,” Int Rev Psychiatry, vol. 30, no. 4, pp. 317–330, Aug. 2018, doi: 10.1080/09540261.2018.1482261. Available: http://dx.doi.org/10.1080/09540261.2018.1482261
[26]P. D. Petridis et al., “Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer,” Nat. Ment. Health, vol. 2, no. 11, pp. 1408–1414, Oct. 2024, doi: 10.1038/s44220-024-00331-0. Available: https://www.nature.com/articles/s44220-024-00331-0
[27]J. M. Mitchell et al., “MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study,” Nat Med, vol. 27, no. 6, pp. 1025–1033, Jun. 2021, doi: 10.1038/s41591-021-01336-3. Available: http://dx.doi.org/10.1038/s41591-021-01336-3
[28]S. B. Armstrong, Y. Xin, N. D. Sepeda, M. Polanco, L. A. Averill, and A. K. Davis, “Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans,” Mil Psychol, vol. 36, no. 2, pp. 184–191, Mar-Apr 2024, doi: 10.1080/08995605.2022.2156200. Available: http://dx.doi.org/10.1080/08995605.2022.2156200
[29]R. L. Carhart-Harris et al., “Psilocybin with psychological support for treatment-resistant depression: six-month follow-up,” Psychopharmacology (Berl), vol. 235, no. 2, pp. 399–408, Feb. 2018, doi: 10.1007/s00213-017-4771-x. Available: http://dx.doi.org/10.1007/s00213-017-4771-x
[30]X. Koenig and K. Hilber, “The anti-addiction drug ibogaine and the heart: a delicate relation,” Molecules, vol. 20, no. 2, pp. 2208–2228, Jan. 2015, doi: 10.3390/molecules20022208. Available: http://dx.doi.org/10.3390/molecules20022208
[31]A. K. Schlag, J. Aday, I. Salam, J. C. Neill, and D. J. Nutt, “Adverse effects of psychedelics: From anecdotes and misinformation to systematic science,” J Psychopharmacol, vol. 36, no. 3, pp. 258–272, Mar. 2022, doi: 10.1177/02698811211069100. Available: http://dx.doi.org/10.1177/02698811211069100
[32]G. Barber, C. B. Nemeroff, and S. Siegel, “A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability,” Am J Psychiatry, vol. 179, no. 12, pp. 892–896, Dec. 2022, doi: 10.1176/appi.ajp.22010073. Available: http://dx.doi.org/10.1176/appi.ajp.22010073
[33]M. W. Johnson, “Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine,” ACS Pharmacol Transl Sci, vol. 4, no. 2, pp. 578–581, Apr. 2021, doi: 10.1021/acsptsci.0c00198. Available: http://dx.doi.org/10.1021/acsptsci.0c00198
[34]S. Robledo, L. Valencia, M. Zuluaga, O. A. Echeverri, and J. W. A. Valencia, “tosr: Create the Tree of Science from WoS and Scopus,” J. Sci. Res., vol. 13, no. 2, pp. 459–465, Aug. 2024, doi: 10.5530/jscires.13.2.36. Available: http://dx.doi.org/10.5530/jscires.13.2.36
[35]“Website.” doi: 10.1007/s00213-024-06620-x. Available: http://dx.doi.org/10.1007/s00213-024-06620-x
[36]B. L. Roth and R. H. Gumpper, “Psychedelics as Transformative Therapeutics,” Am J Psychiatry, vol. 180, no. 5, pp. 340–347, May 2023, doi: 10.1176/appi.ajp.20230172. Available: http://dx.doi.org/10.1176/appi.ajp.20230172
[37]R. R. Griffiths et al., “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial,” Journal of Psychopharmacology, Dec. 2016, doi: 10.1177/0269881116675513. Available: https://journals.sagepub.com/doi/10.1177/0269881116675513. [Accessed: Jul. 12, 2025]
[38]L. Bouchet et al., “Older adults in psychedelic-assisted therapy trials: A systematic review,” J Psychopharmacol, vol. 38, no. 1, pp. 33–48, Jan. 2024, doi: 10.1177/02698811231215420. Available: http://dx.doi.org/10.1177/02698811231215420
[39]“Website.” doi: 10.1007/s11469-024-01253-9. Available: http://dx.doi.org/10.1007/s11469-024-01253-9
[40]R. Palitsky et al., “Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies,” JAMA Psychiatry, vol. 80, no. 7, pp. 743–749, Jul. 2023, doi: 10.1001/jamapsychiatry.2023.1554. Available: http://dx.doi.org/10.1001/jamapsychiatry.2023.1554
[41]R. Palitsky et al., “A critical evaluation of psilocybin-assisted therapy protocol components from clinical trial patients, facilitators, and caregivers,” Psychotherapy (Chic), Jan. 2025, doi: 10.1037/pst0000551. Available: http://dx.doi.org/10.1037/pst0000551
[42]R. B. Kargbo, “Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring,” ACS Med Chem Lett, vol. 16, no. 2, pp. 219–221, Feb. 2025, doi: 10.1021/acsmedchemlett.5c00031. Available: http://dx.doi.org/10.1021/acsmedchemlett.5c00031
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2025 Interfaces
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
